Breakthrough for AlzeCure in the development of drugs for nerve pain
AlzeCure Pharma shows positive results from its clinical study with a new non-opioid drug candidate developed against peripheral neuropathic pain.
New data from AlzeCure’s phase IIa study show that the drug candidate ACD440 has a significant analgesic effect on pain induced by cold and heat.
– The medical need in this area is immense, not least to find alternatives to opioids. Neuropathic pain is the single largest market segment in pain management, generating over $11 billion in annual revenues. Up to 80 percent of all patients do not get a satisfactory effect with their current treatments, said AlzeCure Pharma’s CEO Martin Jönsson.
AlzeCure is among a handful of companies in the world that develop drugs that target the TRPV1 receptor, whose discovery was awarded the 2021 Nobel Prize in Medicine. The goal is to help people who suffer from nerve pain. In many cases today, there is no other effective treatment available than opioids, which both numb the whole body and can lead to addiction and substance abuse.
Chris Heister: “Everyone who has made this journey feels as though they’re fighting the system a bit.”
Even if Chris Heister shifts down a gear when she leaves her role as council leader in Stockholm, she is unlikely be drawing on her pension any time soon. The class journey she has made from growing up in a countryside idyll, north of Stockholm, has given her a momentum that continually drives her forward.
Evren Alici set to make cancer a liveable illness
A recent study could pave the way to treating a type of bone marrow cancer. The aim is to transform the cancer from being incurable to a disease that it is possible to live with. The research behind the study was conducted in Evren Alici’s group at Campus Flemingsberg.
Karin Mellström: “Co-operation is the key to success”
After 10 years as a start-up, CellProtect Nordic Pharmaceuticals has taken a major step forward. Our patient and careful work is now bearing fruit, explains Karin Mellström, CEO and founder. Looking back on her career, she sums it up by saying: “I’d never been bored for a second!”
Matti Sällberg: “Vital to contribute facts to the debate”
During the course of the pandemic, he has appeared on an almost daily basis in the morning papers or on the TV news. Matti Sällberg fast became an expert the media called for help explaining everything from vaccine development to the spread of infection.
